Constaeffective Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 4 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth 180.55%
- Profit Growth -139.79%
- Ebitda 1.28%
- Net Worth -530.09%
- Total Assets 9.34%
About Constaeffective Pharma
Constaeffective Pharma Private Limited (CPPL) is a Private Limited Indian Non-Government Company incorporated in India on 28 September 2017 (Seven years and four months 28 days old ). Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Business Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Shobha Vishwanath and Pramod Kapale serve as directors at the Company.
Company Details
- Location
Thane, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media
Corporate Identity Details
- CIN/LLPIN
U74999MH2017PTC300250
- Company No.
300250
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Sep 2017
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Constaeffective Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shobha Vishwanath  | Director | 05-Jul-2019 | Current |
| Pramod Kapale | Director | 28-Sep-2017 | Current |
Financial Performance of Constaeffective Pharma.
Constaeffective Pharma Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 180.55% increase. The company also saw a substantial fall in profitability, with a 139.79% decrease in profit. The company's net worth observed a substantial decline by a decrease of 530.09%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Constaeffective Pharma?
Unlock access to Constaeffective Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Constaeffective Pharma?
Unlock and access historical data on people associated with Constaeffective Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Constaeffective Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Constaeffective Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
